Skip to main content
Premium Trial:

Request an Annual Quote

Arradial Finds a Haven for Microfluidics Technology

Premium

If it hadn’t been for that summer John Havens spent at Case Western Reserve University’s macromolecular science department as a high-school student, he might not be the senior vice president of technology at microfluidics company Arradial today.

“It was a sponsored program that had one student from each area high school to go up to Case for the summer,” Havens, 45, says. “I went out there and liked and it and the professor kept inviting me back. Eventually I transferred there and did my graduate work with him. Strictly by chance.”

Havens now applies his expertise in high-throughput screening, DNA and protein biochips, and bioMEMs devices to the development and commercialization of Arradial’s platforms, including microfluidic systems for target identification and drug discovery.

Though he operates on a managerial level and handles business development, Havens sometimes misses getting down and dirty in the lab. “I always enjoyed lab work. That’s why I got into science,” he says. “But you can have a lot more leverage by directing groups and interacting on a corporate level.”

Before joining Arradial’s ranks in Massachusetts, Havens was senior director of chemistry and high-throughput screening at Nanogen, where he led platform-development efforts for SNP genotyping and discovery.

At Arradial, Havens is part of an effort to use the microfluidic approach to screen novel targets as well as to generate biochip arrays. The main challenge, he says, is to do all this as quickly as possible with the money that they have raised. “It’s always a time/money sort of game,” he says. “We think we can do it, but you know, the proof is in the pudding.”

— Jasmin Chua

 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.